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Abstract
Splicing of the human vascular endothelial growth factor-A (VEGF-A) gene has been reported to generate angiogenic
(VEGFxxx) and anti-angiogenic (VEGFxxxb) isoforms. Corresponding VEGFxxxb isoforms have also been reported in rat and
mouse. We examined VEGFxxxb expression in mouse fibrosarcoma cell lines expressing all or individual VEGF isoforms
(VEGF120, 164 or 188), grown in vitro and in vivo, and compared results with those from normal mouse and human tissues.
Importantly, genetic construction of VEGF164 and VEGF188 expressing fibrosarcomas, in which exon 7 is fused to the
conventional exon 8, precludes VEGFxxxb splicing from occurring. Thus, these two fibrosarcoma cell lines provided
endogenous negative controls. Using RT-PCR we show that primers designed to simultaneously amplify VEGFxxx and
VEGFxxxb isoforms amplified only VEGFxxx variants in both species. Moreover, only VEGFxxx species were generated when
mouse podocytes were treated with TGFb-1, a reported activator of VEGFxxxb splice selection in human podocytes. A
VEGF164/120 heteroduplex species was identified as a PCR artefact, specifically in mouse. VEGFxxxb isoform-specific PCR
did amplify putative VEGFxxxb species in mouse and human tissues, but unexpectedly also in VEGF188 and VEGF164
fibrosarcoma cells and tumours, where splicing to produce true VEGFxxxb isoforms cannot occur. Moreover, these products
were only consistently generated using reverse primers spanning more than 5 bases across the 8b/7 or 8b/5 splice
junctions. Primer annealing to VEGFxxx transcripts and amplification of exon 8b primer ‘tails’ explained the artefactual
generation of VEGFxxxb products, since the same products were generated when the PCR reactions were performed with
cDNA from VEGF164/VEGF188 ‘knock-in’ vectors used in the generation of single VEGF isoform-expressing transgenic mice
from which the fibrosarcoma lines were developed. Collectively, our results highlight important pitfalls in data
interpretation associated with detecting VEGFxxxb isoforms using current methods, and demonstrate that anti-angiogenic
isoforms are not commonly expressed in mouse or human tissues.
Citation: Harris S, Craze M, Newton J, Fisher M, Shima DT, et al. (2012) Do Anti-Angiogenic VEGF (VEGFxxxb) Isoforms Exist? A Cautionary Tale. PLoS ONE 7(5):
e35231. doi:10.1371/journal.pone.0035231
Editor: Carlo Gaetano, Istituto Dermopatico dell’Immacolata, Italy
Received April 26, 2011; Accepted March 14, 2012; Published May 2, 2012
Copyright:  2012 Harris et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by Cancer Research United Kingdom (Programme Grant Tumour Microcirculation, grant number C1276/A9993. The funders
had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: Sheila.harris@sheffield.ac.uk
Introduction
Vascular endothelial growth factor-A (hereafter referred to as
VEGF) is a key regulator of angiogenesis, a process fundamental
to the growth and metastasis of tumours [1,2]. VEGF mRNA
and protein are up-regulated in many cancers, with high VEGF
levels often being associated with a poor prognosis [3–6]. Not
surprisingly, many current vascular based anti-cancer therapies
are targeted to inhibiting VEGF [7–10]. However, VEGF
biology is complex. Both the human and murine VEGF genes
are comprised of eight exons separated by seven introns [11,12].
In man, at least nine different VEGF isoforms (VEGFxxx;
where x denotes the number of amino acids) have been
described due to alternative splicing of the VEGF gene, the
most common and well studied being VEGF189, VEGF165 and
VEGF121 (VEGF120, VEGF164 and VEGF188 in mouse) [13–
15]. All VEGF isoforms contain exons 1 to 5 and 8 but differ in
composition of remaining exons 6 to 7 (Fig. 1) and consequently
binding to extracellular matrix and neuropilin co-receptors.
VEGF165/164, which lack exon 6 but retain exon 7, represent
the most abundantly expressed VEGF isoform in humans and
mouse respectively [16–18]. The matrix binding characteristics
of individual isoforms are thought to generate gradients in vivo
that are important for angiogenesis [19–21]. While relatively
little is known regarding the mechanistic functions of the
different VEGF isoforms, in vivo studies using isoform-specific
transgenic mice have revealed distinct roles in vascular growth,
branching and patterning during development [22–24]. More
recently, we demonstrated thattransgenic isoform-specific mouse
embryos (VEGF-188, 164 or 120) gave rise to tumours with
distinct morphological and functional vascular characteristics
[25], mirroring some of the effects observed during develop-
ment.
In 2002, a novel family of human VEGF-A splice variants
was described (VEGFxxxb), formed by alternative splicing
downstream of the conventional exon 8 within what was
thought to be the 39 untranslated region (39 UTR) of the VEGF
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gene, resulting in the new open reading frame exon 8b [26].
VEGF165b has been described in normal human tissues, and
shown to exhibit anti-angiogenic activity in vitro [26–33] and in
vivo [26–30,32,34–37]. VEGFxxxb variants have been reported
to account for up to 50% of total VEGF in some normal
human tissues, whilst being down-regulated in cancer [15,27–
31,38,39]. Consequently, these observations led to the sugges-
tion that it is the balance between the two families of VEGF
that ultimately determines angiogenic outcome [15]. As current
anti-VEGF strategies could potentially target both the pro- and
anti-angiogenic forms of VEGF [40], this raises important
questions for cancer therapies. However, there have been few
studies reporting VEGFxxxb isoform expression in normal and
tumour tissues since the initial discovery of VEGF165b [26].
While anti-angiogenic VEGF165b and more recently
VEGF189b [41] and VEGF121b [42] have been described in
man, the expression of these anti-angiogenic variants has only
been described in the mouse at the protein level, using detection
with an antibody that was initially developed for human use
[43]. Therefore it is important to determine whether the mouse
effectively models the human in this regard at both gene and
protein levels. Alignment of the murine and human VEGF-A
genes reveals conservation (86%) of the exon 8b sequence in the
murine VEGF-A gene, predicting the possibility of a VEGFxxxb
splicing reaction in mice. Interestingly, this would result in an
exon 8b encoding seven amino acids (PLTGKTD) compared to
the human exon8b, which encodes six amino acids (SLTRKD).
Here, we use reverse transcriptase PCR (RT-PCR) and
a range of primer designs to dissect VEGF isoform expression
in mouse and human cells and tissues, including tumours. In
particular, we emphasise pitfalls associated with interpretation of
PCR results. The genetic construction approaches used for the
development of the VEGF isoform-specific transgenic mice,
from which our fibrosarcoma cell lines were developed [25],
makes the fibrosarcoma cells particularly useful for our studies.
Specifically, VEGFa120/120 mice were constructed by site-specific
removal of exons 6 & 7, retaining VEGF intronic sequences,
and as such these mice retain the potential to splice into exon
8b to create a putative VEGF120b isoform [22]. In contrast,
the VEGFa164/164 and VEGFa188/188 mice were constructed
using cDNAs encoding exons 4, 5, 7 & 8 (for VEGF164) or 4
to 8 (for VEGF188) [23]. Since in these mice exon 7 is fused to
the conventional exon 8, expression of VEGF164b or
VEGF188b respectively is excluded. Thus, splicing to generate
VEGFxxxb variants could potentially occur in fibrosarcomas
expressing exclusively VEGF120 (or wild type controls) but not
in those expressing only VEGF164 or VEGF188 and hence
these two fibrosarcoma lines provided endogenous negative
controls.
Materials and Methods
Cell Culture and Cell Lines
The VEGF-specific fibrosarcoma cell lines, developed as
described previously [25], were routinely maintained in high
glucose Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% foetal calf serum (FCS), 4 mM L-glutamine,
puromycin (2 mg/ml) and geneticin (600 mg/ml). For the purposes
of RNA extraction, cells were passaged at a ratio of 1:6, 24 hr
prior to harvesting to stimulate gene expression. Proliferating
conditionally immortalised mouse podocytes (PCIPs) were kindly
donated by Dr Jochen Reiser, University of Miami, USA. The
cells were established from the Immortomouse, which carries
a thermosensitive variant of the SV40 transgene. At the permissive
temperature of 33uC, T-antigen expression can be stimulated by
mouse c-interferon (c-INF), allowing rapid cell proliferation. Cells
were routinely maintained in RPMI 1640 medium supplemented
with 10% FCS, 4 mM L-glutamine as described previously [44].
For treatment with growth factors, cells were grown in six well
plates (16105 cells per well) until 95% confluent. After starving for
24 hours in serum free medium, cells were treated with either
100 nM Insulin growth factor 1 (IGF-1) or 1 nM Transforming
growth factor beta 1 (TGFb-1) for 12 hours and processed for
RNA/cDNA extraction as described below. Human embryonic
kidney cells (HEK293) were obtained from the ATCC (CRL-
1573) and maintained in Eagle’s Minimum Essential medium
(EMEM) supplemented with 10% FCS and 4 mM L-glutamine.
For the purposes of RNA extraction, cells were split at a ratio of
1:2 to stimulate gene expression.
Generation of murine subcutaneous tumours and mouse and
human tissue extraction.
All animal experiments were conducted according to United
Kingdom Animals (Scientific Procedures) Act 1986 (UK Home
Office Project Licence PPL40/3110) and with local University of
Sheffield ethical approval. VEGF-specific fibrosarcomas were
generated in vivo as we described previously [25]. Briefly, a cell
suspension (16106 cells in 50 ml) was injected into the rear dorsum
of 8–12 week old female severe combined immunodeficiency
(SCID) mice and tumours were excised when they reached
,8 mm mean diameter in size. Tumours were cut into smaller
pieces and suspended in RNA later (Ambion) overnight at 4uC.
The next day, RNA later was removed and tissues were stored at –
80uC or processed immediately for RNA extraction. Mouse heart,
lung liver and kidney organs, excised from non-tumour-bearing
age-matched female SCID and CBA mice (5 of each), and
a surgical specimen of human kidney tissue, obtained following
ethics approval granted by the Sheffield Research Ethics
Committee (Reference 06/Q2305/27) and patient written con-
sent, were also processed as above.
cDNA Synthesis and RT-PCR
Total RNA was extracted from cultured cells (fibrosarcoma
cells, HEK 293 cells; mouse podocytes) and converted to cDNA
using the Cells to cDNA II kit (Ambion). Total RNA from
tumours, mouse organs and human kidney tissue was extracted
using the MirvanaTM PARISTM kit (Ambion) and converted to
cDNA using the Retroscript kit (Ambion) as per the manufac-
turer’s instructions. Briefly, 70–100 mg of tissue was homogenised
in 500–600 ml of non-ionic detergent buffer supplied in the kit.
Purified RNA was examined by denaturing formaldehyde gel
electrophoresis to assess integrity. Prior to cDNA conversion,
traces of genomic DNA were removed by treating 10 mg of total
RNA with DNAse1 (Turbo DNA-free kit, Ambion). A portion of
the RNA (1.5–2 mg) was then converted to cDNA by oligo-dT
Figure 1. Murine VEGF-A splice variants. Several splice variants of
VEGF are produced, by alternative splicing of exons 6 & 7. Exons 3 & 4
encode dimerisation and VEGF receptor binding sites, exon 7 encodes
neuropilin binding sites and exons 6 & 7 encode heparin binding sites.
doi:10.1371/journal.pone.0035231.g001
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primed reverse transcription. Similar reactions were set up without
reverse transcriptase (-RT) as controls to ensure absence of
genomic DNA contamination. The cDNA (10% of total) was then
routinely amplified in RT-PCR reactions using a number of
different primer pairs. General RT-PCR (mouse): Sequences of all
murine (forward/reverse) primers are shown in Table 1 and
reverse primers highlighted specifically in Fig. 2. When using
primers that could amplify only pro-angiogenic VEGFxxx
isoforms (exon3/exon8 and exon 3/39 UTR-C) or both VEGFxxx
and VEGFxxxb isoforms simultaneously (exon3/39UTR and
exon7a/39UTR), RT-PCR was performed in 50 ml reactions
comprising of 0.5 mM primers, 1.2 mM MgCl2, 200 mM dNTPs
and 1 unit of Taq polymerase (2 6 master mix supplied by
Thermo scientific). Following an initial denaturation step at 94uC
for 2 min, reactions were cycled 35 times, denaturing at 94uC
for 1 min, annealing at 55uC for 1 min, and extending at 72uC for
1 min, followed by a final extension step of 72uC for 5 min.
Approximately 4–20% of each PCR reaction was examined by gel
electrophoresis using 2.5% agarose gels containing 0.5 mg/ml
ethidium bromide. Exon-specific RT-PCR (mouse): When performing
isoform-specific RT-PCR to preferentially amplify VEGFxxxb
isoforms, the same exon 3 or exon 7a forward primers but different
isoform-specific reverse primers were used (see Table 1 & Fig 2).
For detection of VEGF188b and VEGF164b, four different
reverse primers were designed spanning different amounts of exon
7 and exon 8b (164b/188b-1, 164b/188b-2, 164b/188b-3 and
164b/188b-4). To detect VEGF120b, two different reverse
primers were designed spanning different amounts of exon5 and
exon 8b (120b-1 and 120b-2). RT-PCR reactions were performed
routinely using conditions previously described to detect human
VEGF165b [26]. Briefly, this involved an initial denaturation step
at 94uC for 5 min, reactions were cycled 35 times, denaturing at
94uC for 0.5 min, annealing at 55uC or 63uC for 0.5 min, and
extending at 72uC for 1 min, followed by a final extension step of
72uC for 2 min. The same conditions described for general RT-
PCR (mouse) above were also employed to amplify VEGF
isoforms from ‘knock-in’ DNA plasmid vectors (kindly provided
by Dr Patricia D’Amore´) used in the generation of the VEGF
single isoform expressing transgenic mice as templates [23].
Typically 100 ng of template DNA was used in PCR reactions.
RT-PCR using human cell and tissue cDNAs: Sequences of all human
forward/reverse primers are shown in Table 1 and reverse primers
highlighted in Fig 2. RT-PCR was performed using two
independent commercial sources of human cDNA extracted from
cerebral cortex, bladder and kidney (AMS Biotechnology Ltd) and
kidney, prostate and colon (Primer Design Ltd) as well as cDNA
extracted in house from surgical patient normal kidney tissue. RT-
PCR was also performed using HEK293 cDNA alongside mouse
podocyte cDNA. PCR reactions were routinely performed in 25 ml
using 1 ml of cDNA (AMS cDNAs) and 20 ml using 5 ml of cDNA
(Primer Design cDNAs). Following an initial denaturation step at
95uC for 2 min, reactions were cycled 35 times, denaturing at
95uC for 1 min, annealing at 55uC or 63uC for 1 min, and
extending at 72uC for 1 min, followed by a final extension step of
72uC for 5 min. To simultaneously amplify VEGFxxx and
VEGFxxxb isoforms, the forward primers: DB exon4 or DB
exon7a were used together with the reverse primer, DB 39UTR
(Fig. 2). To amplify only VEGFxxxb products, the forward primer:
DB exon4 was used together with reverse primers DB165b/189b-
1, h165b/189b-2, h165b/189b-3, h165b/189b-4 or h165b/189b-
5. Only results of PCR reactions performed at 55uC are shown in
the manuscript.
Efficient PCR conditions were confirmed by using primers
designed to co-amplify GAPDH with VEGFxxxb in the same
reactions. GAPDH products were readily amplified while
transcripts corresponding to VEGFxxxb were undetectable
probably due to preferential amplification of the more abundant
GAPDH gene and depletion of reaction reagents in the system
(data not shown).
Sequencing of PCR Products
PCR products were excised from agarose gels under UV
transillumination, and DNA extracted using the Quiaquick PCR
purification Kit (Quiagen). The DNA was then sequenced using
the exon 3 (for mouse PCR products) or exon 4 (for human PCR
products) forward primers by fluorescent dideoxy termination
sequencing (AB1370). Sequences were analysed by automated
fluorescent chromatography and matched to the chromatograph
manually. To verify the integrity of the murine VEGF 39UTR
exon 8b region in the fibrosarcomas RT-PCR analysis was
performed using forward/reverse primers exon7/8-C and
39UTR2 respectively (see Table 1). DNA Sequence analysis using
the forward primer exon7a verified the integrity of the predicted
exon 8b region and in addition, generated sequence data further
downstream within the 39UTR. Consistent with the different
methods used in the generation of the VEGF164/VEGF164 &
VEGF188/VEGF188 and VEGF120/VEGF120 mice [22,23], an
additional 85 bp sequence within the VEGF164/188 sequence,
initiating at base 1141 (CCTCGAGGGACCTAATAACTTCG-
TATAGCATACATTATACGAAGTTATATTAAGGGT-
TATTGAATATGATCGGAATTGCTCGAGG), was detected
which was not present in the VEGF120 sequence.
Results
Assessment of VEGF Isoform Expression by RT-PCR using
Primers Designed to Amplify Both VEGFxxx and
VEGFxxxb Isoforms
The existence of VEGFxxxb splice variants in human tissues
has been reported in a number of studies using primarily reverse
transcription (RT) PCR based approaches [14,26–
29,38,39,41,42,45,46]. To investigate expression of VEGF
isoforms in our mouse fibrosarcoma cell lines, their correspond-
ing solid tumour extracts and normal mouse and human cells/
tissues, we adopted a PCR approach using primers designed to
amplify VEGFxxx and VEGFxxxb families simultaneously,
consistent with the primer design strategy previously reported
for the identification of human VEGF165b [26]. cDNA extracts
were prepared from mouse fibrosarcoma cells and tumours as
well as mouse heart, lung, liver and kidney organs from two
different strains of mice (CBA and SCID), to accommodate
possible strain differences in VEGF isoform expression. In
addition, two independent commercial sources of cDNA from
human tissues (brain, bladder and kidney cDNAs from AMS
Biotechnology Ltd, and kidney and prostate cDNAs from Primer
Design Ltd) were included as positive controls. As shown in
Fig. 3A–C, using forward and reverse primers designed to the
murine or human exon7 and 39UTR respectively, only one PCR
product corresponding to VEGFxxx (194 bp) was consistently
amplified from all the samples. This result held true for both
independent commercial sources of human kidney cDNA,
despite kidney being previously identified as an abundant source
of VEGF165b [26,31].
To validate these results and enable differentiation of all
VEGF isoforms (ie. including VEGF120b), RT-PCR was
performed on all samples using the same 39UTR reverse
primer(s) but this time an exon 3 forward primer (for mouse)
and an exon 4 forward primer (for human). Again VEGFxxxb
VEGF Isoform Detection
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products would be expected to migrate approximately 66 bp
below their VEGFxxx counterparts. As shown in Figure 4A,
products consistent in size with VEGF188, 164 and 120 isoforms
were detected in wt fibrosarcoma cell lines and tumours, while
only the appropriate single isoform was evident in the isoform-
specific cell lines and tumours, consistent with data we published
previously [25]. Products corresponding to these isoforms were
also detected in our panel of normal mouse tissues, albeit in
differing abundances. Qualitative assessment of this data infers
that VEGF188 appears the most abundant isoform in mouse
lung and is also highly expressed in the heart, whilst VEGF164
appears the predominant isoform in mouse kidney, results
consistent with the literature [47,48]. Similarly, products
corresponding to VEGF121, VEGF165 and VEGF189 were
detected in our panel of human tissue cDNAs (Fig. 4B & C),
however again no VEGFxxxb isoforms were detected, consistent
with our previous mouse and human data (Fig. 3A–C).
Interestingly, a smaller PCR product migrating just below
VEGF164 (,380 bp) was consistently observed in wt fibrosar-
coma cell and tumour cDNAs [25] as well as cDNAs from
normal mouse tissues, especially mouse kidney (see Fig. 4A,
product denoted by arrows). Whilst this fragment was larger than
expected for VEGF164b (323 bp), its presence, hinted to the
possibility that at least for VEGF164, a sister murine VEGFxxxb
isoform might exist. To determine the identity of this PCR
product, high-resolution agarose gel electrophoresis was per-
formed and the band was excised, purified and sequenced. The
resultant chromatogram revealed a mixed sequence, whereby the
sequence diverged at the end of exon 5, common to all VEGF
isoforms, and then resolved to a single readable sequence again
at the 39 end. Analysis of this sequence showed that it resolved to
a mixture of VEGF164 and VEGF120, suggesting that these two
isoforms formed a heteroduplex. RT-PCR reactions performed
using a mixture of cDNA templates from VEGF164 and
VEGF120 tumours confirmed heteroduplex generation, since
under these conditions a similar PCR product migrating just
below the corresponding VEGF164 product was observed
(Fig. 4D). DNA sequencing of this product revealed the same
heteroduplex sequence described above (data not shown). To
prove conclusively that this product is a PCR artefact and not
a VEGFxxxb product derived from circulating mouse cells that
infiltrated the tumours, the same proof of principle PCR was also
performed using a mixture of cDNA templates isolated from the
fibrosarcoma VEGF164 and VEGF188 cell lines. As shown in
Figure 2. C-terminal exon sequences of murine and human VEGF-A genes. Top two panels show the predicted splicing reactions for murine
VEGF188b, 164b and 120b (sequence in bold and arrowed), highlighting the exon 7/exon 8b and exon 5/exon 8b splice junction sequences. These
splicing reactions would generate putative VEGFxxxb protein isoforms with a PLTGKTD C-terminus. The reverse PCR primers designed for this study
are indicated below the exon sequences. The lower panel shows the corresponding sequence of the human VEGF-A gene C-terminus highlighting
the exon 7/exon 8b splice junction that generates VEGFxxxb isoforms with a SLTRKD C-terminus. The reverse PCR primers used in the amplification
reactions are indicated below the exon sequences and DB 165b/188b-1 and DB 3’UTR are as previously published [26]. The bases highlighted in bold
exhibit mismatches from the published human VEGF-A sequence.
doi:10.1371/journal.pone.0035231.g002
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Figure 4E the same heteroduplex product was observed, thus
confirming that VEGF164/120 can form a heteroduplex in RT-
PCR reactions. Moreover, this confirmed that this transcript did
not represent VEGFxxxb.
To address more conclusively VEGFxxxb expression in mouse,
we next performed mechanistic studies using growth factors
reported to influence VEGF splice site selection choice in human
podocytes (PCIPs) [14,32]. Murine podocytes were grown at the
permissive temperature of 33uC and then treated with either IGF-
1 (reported to favour proximal splice site selection in exon 8 and
VEGFxxx expression in human PCIPs) or TGFb-1 (reported to
favour distal splice site selection in exon 8 and VEGFxxxb
expression in human PCIPs). As shown in Figure 5, RT-PCR
using the exon7a/39UTR primers only amplified VEGFxxx
isoforms, for which there was qualitatively increased expression
with addition of either growth factor. Interestingly, the same RT-
PCR strategy also only amplified VEGFxxx species from HEK293
cells previously reported to express both VEGFxxx and
VEGFxxxb isoform families [32]. Three repeats of these
experiments are highlighted in Figure 5.
Assessment of VEGF Isoform Expression by VEGFxxxb
Isoform Specific RT-PCR
Results described above suggested that VEGFxxxb isoforms
were not expressed in the fibrosarcoma cells, tumours and normal
mouse and human cell lines and tissues tested. To investigate this
more stringently, discriminating isoform-specific RT-PCR was
performed using the same forward primers as previously, but
reverse primers designed to exclusively amplify murine
VEGF164b and VEGF188b (exon3/164b/188b-1) and human
VEGF165b and VEGF188b (DB exon4/DB165b/189b-1), which
span the corresponding exon8b/exon7 splice junctions (see Fig. 2).
As shown in Figure 6A, contrary to the literature, and consistent
with our previous results, no VEGFxxxb products were detected in
human cDNAs using a reverse primer spanning 5 bases
complimentary in sequence to exon 7 (DB165b/189b-1). In
contrast, several PCR products were detected in our panel of
mouse cDNAs using a similar primer containing 5 bases
complimentary in sequence to the murine exon 7 (Fig. 6B).
DNA sequencing revealed that the abundant species, approxi-
mately 150 bp (Fig. 6B & C, product a) in all samples, represented
a novel truncated VEGF transcript comprising exons 3, 4 and 8b,
while the less abundant product, approximately 300 bp in wt
tumours and heart and kidney mouse tissues (Fig. 6B, product b)
corresponded to a putative VEGF164b transcript as confirmed by
the presence of an exon7/exon8b junction sequence. The faint
product migrating just above the 400 bp marker (Fig. 6B, product
c) exhibited 100% identity to acetyl co-A acetyl transferase.
However, of these products, only the truncated VEGF was
reproducibly amplified in repeats of this experiment. Indeed this
was the only species detected in the mouse fibrosarcoma cells
(Fig. 6C) using this strategy. Repeating the strategy, with a murine
VEGF120b specific reverse primer (120b-1) spanning 5 bases
complimentary in sequence to exon 5 failed to reveal VEGF120b
products in any mouse samples (Fig. 6D).
Further Assessment of VEGFxxxb Isoform Expression in
Mouse Fibrosarcoma Tumours Expressing All or Single
VEGF Isoforms using a Refined Panel of VEGFxxxb
Isoform-specific PCR Primers
While the isoform-specific RT-PCR above did detect a putative
VEGF164b product in wt fibrosarcoma tumours (as well as mouse
heart and kidney), the irreproducibility associated with its
detection made it difficult to formally determine whether it
indeed represented a bonafide transcript. To address this more
stringently, RT-PCR was performed next using cDNA extracted
from fibrosarcoma tumours and a panel of refined isoform-specific
primers, varying in the amount of sequence spanning the exon7/
exon8b splice junction (see Fig. 2). For completeness, similar
reactions were also performed in parallel using VEGFxxx isoform-
specific primers, to ensure efficient PCR conditions. As shown in
Fig. 7A, RT-PCR using primers designed to amplify VEGFxxx
products (exon3/exon8) detected VEGF121, 164 and 188 in the
tumour samples. Interestingly, when the same forward primer was
used together with a reverse primer incorporating seven bases of
exon 8b complementary sequence and fourteen bases of sequence
complementary to exon7 (primer 164b/188b-2), products corre-
sponding to VEGF164b (311 bp) were amplified in wt, 164 and
120 tumours, whilst a product corresponding to VEGF188b
(383 bp) was amplified from VEGF188 tumours. Sequencing of
all PCR products generated with the VEGFxxxb reverse primer
Table 1. Mouse and human PCR primer sequences.
Mouse Primers
Mouse (Forward) Tm
exon3 CAGGCTGCTGTAACGATGAA 60uC
exon7a GTTTGTCCAAGATCCGCAGAC 64uC
exon7/8-C GTTAAACGAACGTACTTGCAGATG 68uC
GAPDH-F GCACAGTCAAGGCCGAGAAT 62uC
Mouse (Reverse)
exon8 ACCGCCTCGGCTTGTCACAT 64uC
39UTR-C CTTTCCGGTGAGAGGTCTGG 64uC
39UTR GACATGGTTAATCGGTCTTTCC 64uC
39UTR-1 GCATCCGAGTGAGGACATC 60uC
39UTR-2 CCAGAAACAACCCTAATCTTCC 64uC
164b/188b-1 CTTTCCGGTGAGAGGTCTGCA 66uC
164b/188b-2 GAGAGGTCTGCAAGTACGTTC 64uC
164b/188b-3 CTTTCCGGTGAGAGGTCTGC 64uC
164b/188b-4 CGGTGAGAGGTCTGCAAGTACGTT 54uC
120b-1 CTTTCCGGTGAGAGGTTTTTC 62uC
120b-2 GAGAGGTTTTTCTGGCTTTGTCC 68uC
GAPDH-1 GCCTTCTCCATGGTGGTGAA 62uC
Human Primers
Human (Forward)
DB exon4 GAGATGAGCTTCCTACAGCAC 64uC
DB exon7a GTAAGCTTGTACAAGATCCGCAGACG 78uC
Human (Reverse)
DB165b/189b-1 TCAGTCTTTCCTGGTGAGAGATCTGCA 80uC
h165b/189b-2 CTGGTGAGAGATCTGCA 52uC
h165b/189b-3 TCCTGGTGAGAGATCTGCA 58uC
h165b/189b-4 TGGTGAGAGATCTGCAAGTACGTT 51uC
h165b/189b-5 GAGAGATCTGCAAGTACGTTC 47uC
DB 39UTR ATGGATCCGTATCAGTCTTTCCT 66uC
DB exon8 TCACCGCCTCGGCTTGTCACAT 70uC
The sequences of all forward and reverse PCR primers used in this study are
highlighted along with their corresponding melting temperatures. The junction
spanning details of the VEGFxxxb isoform-specific primers are discussed in the
main text (highlighted in bold above).
doi:10.1371/journal.pone.0035231.t001
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confirmed presence of the exon7/exon8b junction sequence as
defined by the primer design. The VEGF164b product detected in
the VEGF120 fibrosarcomas could in principle reflect VEGF164b
derived from the mouse host. However, when the RT-PCR was
repeated using the same forward primer (exon3) but a reverse
primer, which this time incorporated 16 bases of exon 8b
complimentary sequence and only 4 bases of complimentary
sequence to the end of exon7 (164b/188b-3), no VEGFxxxb
products were obtained (Fig. 7B), even when higher stringency
PCR conditions (63uC) were used (data not shown). Although very
faint bands were evident in all four tumour types using this
VEGF164/188b reverse primer (approximately 380 bp) these
were not of the expected size for VEGFxxxb products
(VEGF188b: 392 bp and VEGF164b: 320 bp) and furthermore
were consistent in size across all four tumour lines, strongly
suggesting that they were non-specific amplification artefacts
(Fig. 7B). It should be noted that as defined by the VEGF-A gene
sequence, the last 3 bases of exon 7 (59CAG39) are in common with
the 3 bases prior to the start of exon8b within the 39UTR,
necessitating that at least 4 bases of sequence complementary to
exon 7 have to be included before the primer becomes ‘isoform-
specific’ (see Fig. 8). To demonstrate the isoform-specificity of
these primers, a further control reverse primer (39UTR-C) was
also included which incorporated the same 16 bases of exon8b
complementary sequence but 4 bases complementary to the 4
bases of murine VEGF-A 39UTR sequence prior to the start of
exon8b, and therefore did not span the VEGFxxxb/xxx splice
junction. As such, this primer could amplify both VEGFxxx and
VEGFxxxb isoforms. As shown in Figure 7B, products corre-
sponding to VEGFxxx isoforms as well as the VEGF164/120
heteroduplex were observed using the control reverse primer,
consistent with efficient PCR, and our previous data (Fig. 4D).
However, no products corresponding to VEGFxxxb isoforms were
detected. Together, these results suggested that the putative
VEGFxxxb products observed are artefactual VEGFxxxb prod-
ucts obtained through mispriming of the reverse primer from
existing VEGFxxx transcripts. To address this more conclusively,
and to remove possible ambiguities associated with using tumour
cDNA extracts, we next performed similar RT-PCR reactions as
described above, but this time using cDNAs extracted from
fibrosarcoma cells expressing either all (wt) or single VEGF
isoforms. In parallel we also tested the same primer combinations
on plasmid DNAs corresponding to the original ‘knock-in’ vectors
used to create the VEGF164- and VEGF188-expressing trans-
genic mice. We argued that PCR using these purified plasmid
DNAs would provide a definitive control to demonstrate the
possibility that any putative VEGFxxxb products detected were
indeed artefactual, since the nature of construction of these
Figure 3. A general RT-PCR approach with primers to exon 7a and 3’UTR failed to detect VEGFxxxb isoforms in human and mouse
cDNA extracts. RT-PCR reactions were performed using forward/reverse primers designed to amplify both VEGFxxx and VEGFxxxb isoforms from
cDNAs extracted from mouse fibrosarcoma cell lines & tumours and normal mouse tissues (heart, lung, liver and kidney) as well as commercially
sourced human tissue cDNAs. A, A single product corresponding to VEGF164/188 (194 bp) is evident in the panel of mouse cDNAs using forward and
reverse primers designed to exon 7 and the 3’UTR (exon7/39UTR) with no evidence of VEGF164b/188b (128 bp) products. B & C, A single product
corresponding to VEGF165/189 (194 bp) is evident in human brain, bladder and kidney (AMS Biotechnology Ltd), and prostate and kidney (Primer
Design Ltd) using forward and reverse primers designed to exon 7 (DB exon7a) and the 3’UTR (DB 3’UTR) respectively. No products corresponding to
VEGF165b/189b (128 bp) are evident in any of these samples.
doi:10.1371/journal.pone.0035231.g003
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Figure 4. A general RT-PCR approach using primers to exon 3 or 4 and 3’UTR failed to detect VEGFxxxb isoforms in mouse and
human cDNA extracts respectively. A, PCR products corresponding to VEGF188 (474 bp), VEGF164 (402 bp), VEGF164/120 heteroduplex
(arrowed) and VEGF120 (270 bp) are evident in the panel of mouse cDNAs amplified using the 39UTR reverse primer and a forward primer to exon 3.
B & C, PCR products corresponding to VEGF189 (371 bp), VEGF165 (299 bp) and VEGF121 (167 bp) are evident in the commercial human tissue
cDNAs amplified using the 39UTR reverse primer (DB 3’UTR) and a forward primer to exon 4 (DB exon4). D, Amplification of the heteroduplex species
(arrowed) a lso occurred when VEGF164 and VEGF120 tumour cDNAs were pooled and analysed by RT-PCR using exon3/3’UTR primers (lanes labelled
120+164). E, The same heteroduplex species was generated when cDNAs from VEGF164 and VEGF188 expressing fibrosarcoma cells were pooled and
amplified as above (lanes labelled 120+164). M corresponds to a 100 bp ladder, whilst -tem represents a control PCR reaction in which water was
used instead of cDNA template. The Figure contains data we published previously [25].
doi:10.1371/journal.pone.0035231.g004
Figure 5. Effect of IGF-1 and TGFb-1 on expression of VEGF isoforms in mouse podocytes. Cell lysates were prepared from untreated
control (C) podocyte cells or cells treated with either 100 nM IGF-1 (IGF) or 1 nM TGFb-1 (TGF) for 12 hours in serum free media. Results from three
independent experiments are shown. RT-PCR using general primers designed to simultaneously amplify both VEGFxxx and VEGFxxxb isoforms
(exon7a/3’UTR) revealed only VEGFxxx (194 bp). Qualitative assessment of the PCR products suggests that treatment with either growth factor
increased VEGFxxx expression. The same RT-PCR strategy using three different extracts (1, 2, 3) from HEK 293 cells similarly revealed only VEGFxxx
(194 bp). (-tem) corresponds to reactions containing water instead of cDNA. (-RT) corresponds to reactions containing water instead of reverse
transcriptase.
doi:10.1371/journal.pone.0035231.g005
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plasmids (the fact that in both cases exon 7 of VEGF cDNA was
fused to exon 8), precludes VEGFxxxb splicing. Interestingly, as
shown in Figs. 7 C, D & E, as the reverse primer design
incorporated increasing complementarity to exon 7 across the
exon8b/7 junction (from 5 bases across in Fig. 7C to 13 & 14
bases across in Fig. 7D & E respectively, see Table 1) putative
VEGF164b and VEGF188b products were increasingly detected
in the corresponding cell extracts. Most importantly however,
abundant amplification products were observed for VEGF164b
and VEGF188b using plasmid DNA as a template, thus proving
conclusively that VEGFxxxb isoform specific reverse primers can
amplify artefactual VEGFxxxb products from existing VEGFxxx
templates. It should be noted that the products generated using
the plasmid cDNAs differed in size from the corresponding
products amplified from fibrosarcoma cDNAs. This is due to the
design of the ‘knock-in’ vectors in which the VEGF cDNAs
inserted into the pPNT backbone to create pPNT.VEGF164 and
pPNT.VEGF188 respectively [23], retain the intron following
exon3 (826 bp), so that the corresponding artefactual VEGF164b
and VEGF188b amplified products would be 1137 bp
(VEGF164b) and 1209 bp (VEGF188b) respectively. For com-
pleteness, and to provide further proof of principle, we next
revisited our VEGF120 PCR data to determine whether
manipulating the primer design around the exon8b/exon5 splice
junction could influence the products detected. Interestingly,
Figure 7F shows that a product (179 bp) was indeed now
amplified in VEGF120 fibrosarcomas, using a reverse primer
(120b-2) incorporating 16 bases of complementary sequence to
exon 5, despite being undetected previously using a primer
spanning only 5 bases of complementary sequence to exon 5
(120b-1). We believe this product represents a VEGF120 isoform,
and the same product detected in the other isoform-specific
fibrosarcomas, reflect VEGF120 derived from the mouse host,
consistent with mispriming of the reverse primer from VEGFxxx
species. Alternatively, since VEGF164 and VEGF188 contain
exons 1–5, there is the possibility that this product was generated
Figure 6. Characterisation of VEGF isoform expression in mouse and human cDNA extracts using VEGFxxxb isoform-specific RT-
PCR. A, RT-PCR using an exon 4 forward primer (DB exon4) and an exon8 b/7 isoform-specific reverse primer (DB165b/189b-1) failed to detect any
PCR products in commercial human tissue cDNAs (AMS Biotechnology Ltd.). B & C, RT-PCR using an exon 3 forward primer and a reverse primer
designed to amplify VEGF164/188 (164b/188b-1) detected a single PCR product in mouse fibrosarcoma cell lines, as well as a number of PCR products
in solid fibrosarcomas and normal CBA and SCID mouse tissues. Product a represents a truncated VEGF species containing exons 3, 4 & 8b. Product
b represents a product identical in sequence to VEGF164b. Product c represents a product exhibiting 100% identity to murine acetyl co-A acetyl
transferase. D, No products corresponding to VEGF120b were detected in mouse cDNAs when RT-PCR was performed using the same exon 3 forward
primer but a reverse primer designed to amplify VEGF120b (120b-1).
doi:10.1371/journal.pone.0035231.g006
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through annealing and mispriming of the reverse primer from
exon5 in VEGF164 and VEGF188 species in these tumours
rather than mouse host cells. This was confirmed when a similar
result was obtained using cDNA templates extracted from the
corresponding fibrosarcoma cell lines (see Fig. 7G). Collectively,
these data strongly suggested that none of the fibrosarcoma
tumours express VEGFxxxb isoforms.
It was surprising that, in our hands, the primer pair reported in
the literature to amplify human VEGFxxxb isoforms failed to
reveal VEGFxxxb transcripts in any of the human commercial
cDNA extracts tested (DBexon4/DB165b/189b-1). However,
closer examination of the melting temperatures (Tm) of these
forward and reverse primers revealed that they differed in Tm by
almost 20uC, conditions unfavourable for successful PCR
amplification. To address this, we revisited the human VEGFxxxb
isoform-specific primer design strategy and performed repeat
reactions using the previous primer pair but this time including
two additional isoform-specific reverse primers (h165b/189b-2 &
h165b/189b-3) which spanned the same 5 bases across the 8b/7
junction but which had Tms similar to, and therefore more
compatible with the forward primer (see Fig. 2). Interestingly,
Figure 9A (lanes 2 & 3) shows that a putative VEGF165b product
could now be detected in the commercial colon, prostate and
kidney cDNAs (Primer Design). Moreover the apparent product
appeared more abundantly amplified (lanes 4 & 5), when the
reverse primer was manipulated to contain fewer bases comple-
mentary in sequence to exon 8b (either 7 or 11 bases, see Fig 2)
and more bases complementary in sequence to the end of exon 7
(either 13 or 14, see Fig 2). An additional putative VEGF189b
product was also evident when using these reverse primers (lanes 4
& 5, upper band). The same putative VEGF165b product was also
obtained using cDNA extracted in house from normal human
kidney (Fig. 9B). Since the PCR strategy using primers designed to
simultaneously amplify both VEGFxxx and VEGFxxxb isoforms
failed to amplify VEGFxxxb species from any of these samples
(Fig 9C), this would argue that the products described above could
represent misprimed VEGF165 and VEGF189 species (with an
artefactual 8b ‘tail’) which increases in intensity when there are
more complimentary bases to exon 7 promoting better annealing
of the primers. Moreover, the fact that products differed in
Figure 7. Discriminating VEGF isoform-specific RT-PCR highlights the importance of primer design in influencing detection of
putative VEGFxxxb products. RT-PCR was performed using an exon 3 forward primer together with different VEGFxxxb isoform specific reverse
primers designed to detect VEGF188b and/or VEGF164b or VEGF120b. A, RT-PCR using a reverse primer spanning 13 bases across the exon8b/exon7
junction (164b/188b-2) amplified a putative VEGF164b (311 bp) product in wt, VEGF164 & VEGF120-expressing tumours and a putative VEGF188b
product (383 bp) in VEGF188-expressing tumours. B, More discriminating RT-PCR using a 164b/188b-3 reverse primer spanning only 4 bases across
the exon8b/7 splice-junction failed to reveal VEGFxxxb PCR products. The ability to detect VEGFxxx products in reactions using exon8 and 39UTR-C
reverse primers highlights efficient PCR conditions. C, No products corresponding to VEGFxxxb isoforms were generated by RT-PCR using cDNA from
mouse fibrosarcoma cells and a reverse primer spanning 5 bases across the exon8b/7 junction (164b/188b-1); VEGF188b (1209 bp) and VEGF164b
(1137 bp) products were amplified from pPNTVEGF164 (V164) & pPNTVEGF188 (V188) ‘knock-in’ plasmid vector cDNA templates [23]. D & E, Putative
VEGF188b and/or VEGF164b products were detected in RT-PCR reactions using reverse primers spanning 13 bases across the exon8b/7 junction
(164b/188b-2 & 164b/188b-4) in fibrosarcoma cells and pPNTVEGF164 & pPNTVEGF188 plasmids. F & G, Products corresponding to VEGF120b (179 bp)
species were readily detected in all fibrosarcoma tumour and cell extracts with a VEGF120-specific reverse primer spanning 16 bases across the
exon8b/5 junction (120b-2), whilst no VEGF120b products were generated when the reverse primer spanned only 5 bases across the 8b/5 junction
(120b-1).
doi:10.1371/journal.pone.0035231.g007
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abundance (compare lanes 2 & 3 with 4 & 5) despite the fact that
equivalent amounts of cDNA were used in the isoform-specific
PCR reactions further supports this argument. It should be noted
however that the putative VEGF165b products in Figure 9A, lanes
2 & 3 were slightly smaller than those in lanes 4 & 5. Sequencing
revealed that indeed products in lanes 4 & 5 corresponded to
VEGF165b, while products in lanes 2 & 3 showed 100% identity
to an unrelated gene, namely LIM domain only protein 7 isoform.
Hence, only when the VEGFxxxb reverse primer shows more
complementarity to exon 7, across the exon8b/7 junction are
putative products corresponding to VEGF165b generated, con-
sistent with the data obtained in mouse using our refined panel of
VEGFxxxb isoform-specific primers.
Discussion
VEGF isoforms have always been considered as pro-angiogenic
until recent reports described corresponding anti-angiogenic
counterparts, formed by distal splicing of exon 8 of the VEGF
gene. Using an RT-PCR based approach we were consistently
unable to detect VEGFxxxb expression in mouse and human cells
and tissues. Importantly, our results demonstrate that any
VEGFxxxb-like transcripts that we did detect were most likely
misprimed VEGFxxx amplification artefacts, highly dependent on
PCR primer design. Recent literature addressing VEGF165b
levels in normal human tissues by RT-PCR and ELISA-based
approaches suggests that VEGFxxxb accounts for more than 50%
of total VEGF in pancreatic islets, colon and vitreous humour, and
a significant proportion in kidney lung and prostate [15].
However, our data questions this interpretation, since surprisingly,
we did not detect VEGFxxxb in cDNAs extracted from tissues or
cells previously reported to express VEGF165b abundantly
[15,26,27,49]. Analysis of human kidney cDNAs from two
independent commercial sources as well as cDNA we prepared
‘in house’ from kidney and HEK293 cells confirmed this finding.
Similarly, mouse podocytes only expressed VEGFxxx, even
Figure 8. Exon splice junction sequences in the murine and human VEGF-A genes. Exon junction sequences are shown for the murine
VEGF-A gene (A) and human VEGF-A gene (B), highlighting the sequence TGCAG, which exists at the end of exons 3, 4 & 7 (in-frame stop codons are
asterisked). Since any VEGF164b/188b reverse primer sequence will contain sequence complementary to these bases, this highlights the possibility of
obtaining truncated VEGF PCR products. The sequence CAG also occurs within the 39UTR, immediately prior to the start of the predicted exon8b
sequence (shown in italics), demonstrating the need for VEGF164b/18b isoform-specific primers to contain a minimum of four bases that span the
exon8b/exon7 junction.
doi:10.1371/journal.pone.0035231.g008
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following stimulation with TGFb-1 reported to favour VEGFxxxb
splice site selection in their human counterparts [14]. 39UTR
reverse primers designed to detect both pro- and anti-angiogenic
VEGF families detected normal pro-angiogenic VEGFxxx prod-
ucts in both mouse and human cells and tissues, confirming that
the PCR technique was effective. Qui et al., recently suggested that
VEGFxxx isoforms may amplify preferentially in PCR reactions,
even when VEGFxxx and VEGFxxxb transcripts are present at
similar abundance. They proposed that differences in 39UTR
secondary structure between VEGFxxx and VEGFxxxb tran-
scripts could cause differential reverse transcription efficiencies
resulting in biased amplification in favour of VEGFxxx [15].
Whilst such a hypothesis could go some way towards explaining
both our mouse and human data, it still does not adequately
explain why we were so consistent in our inability to detect
VEGFxxxb in human samples, since despite these potential
structural issues, successful amplification of VEGFxxxb isoforms
in the same tissues has been reported previously using this strategy
[26,28,29,39]. Moreover, no issues with cDNA synthesis strategies
to accommodate potential structural issues have been discussed in
previous studies reporting detection of VEGF165b, supporting the
cDNA synthesis strategy adopted here. Interestingly, this approach
did reveal a VEGF164/120 heteroduplex product migrating just
below VEGF164 in wt solid fibrosarcomas and fibrosarcoma cells,
as well as in all mouse tissues examined. Such a species has been
reported previously in the literature and is thought to arise as
a consequence of the PCR reaction itself [50]. Importantly, the
heteroduplex species migrates in a manner analogous to
Figure 9. Discriminating VEGF isoform-specific RT-PCR using human cDNA extracts further highlights the importance of primer
design. A, Human cDNAs from colon, prostate and kidney (Primer Design Ltd) were amplified in RT-PCR reactions using an exon 4 forward primer
together with either DB165b/189b-1 (lane 1), h165b/189b-2 (lane 2), h165b/189b-3 (lane 3), h165b/189b-4 (lane 4) or h165b/189b-5 (lane 5). Primer
sequences are highlighted in Table 1 & Fig 2. A putative VEGF165b (,212 bp) product is evident in lanes 2 & 3, but absent in lane 1. All three reverse
primers spanned 5 bases across the 8b/7 junction, however differed in their melting temperatures (see main text), with h165b/189b-2 & 3 exhibiting
more compatible Tms with the forward primer. A similar 165b product was more abundantly amplified in lanes 4 & 5 using reverse primers spanning
more bases (13 or 14 respectively) across the 8b/7 splice junction. In addition, these latter reverse primers also amplified a product corresponding to
188b (,283 bp). However DNA sequencing revealed that the product amplified in lanes 2 & 3 was not VEGF but LIM domain only, protein isoform 7,
confirming that detection of apparent VEGFxxxb species was only evident using 8b/7 reverse primers with increasing complementary sequence to
exon7. B, Similar results were obtained in RT-PCR reactions using cDNA extracted from a normal kidney patient biopsy and amplified with the exon 4
forward primer and the DB165b/189b-1 (lane1), h165b/189b-2 (lane 2) and h165b/189b-4 (lane 4) reverse primers. C, RT-PCR using the DBexon7/
DB3’UTR forward/reverse primers capable of simultaneously amplifying VEGFxxx & VEGFxxxb, confirmed only VEGFxxx (194 bp) amplification in the
human samples tested.
doi:10.1371/journal.pone.0035231.g009
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VEGF145/144, a relatively rare VEGF isoform, highlighting the
importance of sequencing all RT-PCR products in such studies, to
be sure of their true identity. Heteroduplex formation could
generally be an issue when considering PCR amplification of
alternative splice variants. This is supported by the demonstration
that heteroduplex species were generated when analysing isoforms
of apoptosis regulators bcl-x [51] and caspase 10 [52].
Using a VEGFxxxb isoform-specific priming strategy, howev-
er, we did detect VEGFxxxb-like products in both mouse and
human samples confirmed by DNA sequencing. However, the
ability to detect these products was highly dependent on primer
design, and was particularly dependent on the number of primer
bases of complementary sequence spanning the exon8b/exon7
(for detection of VEGF164b/165b, 188b/189b products) or
exon8b/exon5 splice junctions (for detection of VEGF120b/121b
products). We believe this becomes important in analysing our
data. Here, ability to detect VEGFxxxb products decreased as
primer design became more discriminating towards VEGFxxxb
amplification and this applied to both mouse and human cells
and tissues. Thus, VEGFxxxb products were consistently
amplified only when the reverse primer contained more bases
of complementary sequence to exon7 or exon5 as opposed to
exon8b. However, as discussed earlier, the VEGF188 and
VEGF164 fibrosarcomas are inherently unable to splice the
corresponding VEGFxxxb isoforms. It was also surprising that
these VEGFxxxb products were generated at such high
abundances (at least in wt and 188 tumours), since VEGFxxxb
species are thought to be greatly down-regulated in tumours. We
therefore propose that these products most likely represent
misprimed VEGFxxx isoforms, amplified through annealing of
the reverse primer to endogenous VEGFxxx transcripts. These
transcripts exhibit an artefactual C-terminal exon 8b sequence as
a consequence of exon 8b primer ‘tail’ amplification. This could
explain why it became harder to detect putative VEGFxxxb
products with primers exhibiting less sequence complementarity
to exons 5 or 7, presumably through a decrease in probability for
these primers to anneal to and successfully amplify endogenous
VEGFxxx transcripts. Interestingly, we only detected VEGF164b
with a reverse primer containing 5 as opposed to 4 bases
complementary to exon 7, suggesting that this is the minimum
number required to promote better annealing of the primer.
However, this small amount of complementary sequence could
mean that annealing is haphazard, accounting for the re-
producibility issues we had with the detection of this species,
especially at more stringent annealing temperatures. Analysis of
the exon splice junction sequences in both the mouse and human
VEGF-A genes reveals an identical sequence 59TGCAG39 present
at the end of exons 3 and 4 as well as exon 7 (Fig. 8). On this
basis, we hypothesise that any VEGFxxxb reverse primer
designed to amplify VEGF164b/165b and VEGF188b/189b
could in theory prime VEGFxxx and additional truncated
products as a consequence of the PCR reaction. This is
supported by detection of a 150 bp VEGF exon3/4/8b product
in all mouse cDNAs, (Fig 6B & C). An intriguing possibility is
that such truncated products could be primed from an existing
bonafide VEGFxxxb transcript and appear more abundant
simply because they are smaller and more readily amplified.
However, the fact that the VEGF exon 3/4/8b species was
readily detected in all fibrosarcomas including ones that could
not splice into exon 8b makes this interpretation untenable. Our
mispriming hypothesis is further strongly supported when
considering RT-PCR data obtained using either cDNA extracts
from VEGF164 and VEGF188 fibrosarcoma cells or plasmid
DNAs corresponding to vectors used in the original construction
of the VEF164 and VEGF188 expressing transgenic mice which
cannot, due to their genetic construction splice VEGFxxxb
isoforms. Here, the fact that all the VEGFxxxb isoform-specific
primers that we employed generated plasmid-borne putative
VEGFxxxb products misprimed from the VEGFxxx cDNAs
inserted into the vectors, is most likely explained by the high
abundance of purified VEGF cDNA available for the PCR
reactions. Moreover, further support of our mispriming hypoth-
esis is provided by the fact that both mouse and human
VEGFxxxb isoform-specific primers spanning only 5 bases across
the corresponding exon8b/7 junctions were able to amplify non-
specifically, acetyl co-A and LIM domain only protein 7 isoform
gene transcripts. We presume this occurred through mis-priming
of primer through 59GCAT39 and 59GCAG39 sequences present in
these two genes respectively. Whilst no studies have so far
addressed VEGFxxxb isoform expression in the mouse, Artac et
al., have recently reported the expression of VEGF188b and
VEGF164b in the rat ovary [53]. This is intriguing considering
that exon 8b is 100% conserved between rat and mouse. In their
study, these authors used an isoform-specific real-time PCR
approach but they did not report on any analyses using reverse
primers capable of amplifying both the VEGFxxx and
VEGFxxxb isoforms. Close examination of their primer design
reveals that the reverse primer incorporated more complemen-
tary sequence to exon 7 (16 bases) than exon 8b (9 bases),
a primer design, which in our study clearly yields VEGFxxx
products exhibiting an artefactual exon 8b tail sequence.
Several studies have used the only commercially available anti-
VEGFxxxb antibody (anti-human VEGF165b monoclonal anti-
body (clone 56–1 R&D Systems) for detecting VEGFxxxb isoforms
at the protein level in rat and mouse tissues [43,53,54]. However,
in our hands, this antibody unexpectedly detected protein(s) of
equal size across our different isoform-specific mouse fibrosarcoma
cell and solid tumour lines (Data S1). Furthermore, mass
spectrometry of the 27 kDa protein band that was detected by
the antibody in fibrosarcoma cell-conditioned media failed to
identify VEGFxxxb proteins (data not shown). This puts into
question the suitability of this antibody for analysing VEGFxxxb
proteins in mouse and possibly rat which has a predicted 8b
sequence (PLTGKTD) 100% homologous to that predicted for
mouse.
In conclusion, we have presented compelling evidence that
VEGFxxxb isoforms may not be commonly expressed in mice,
and this might go some way to explaining the absence, as yet,
of any VEGFxxxb transgenic mouse model. Interestingly, in
support of our data, it is worth noting that the original Vegfa164/
164 and Vegfa188/188 transgenic mice, that are incapable of
expressing VEGFxxxb isoforms, did not exhibit hyper-vascular
phenotypes, as might be expected if VEGFxxxb isoforms play
an important role in counteracting the pro-angiogenic isoforms
under normal circumstances. Indeed, the Vegfa164/164 mice, in
particular, appeared relatively normal [23], suggesting that any
lack of anti-angiogenic isoforms has no major deleterious effects.
Taken together, our data clearly highlight pitfalls associated
with interpreting VEGF expression patterns. The general
importance of RT-PCR primer design is highlighted, with
a need for multiple approaches to discriminate isoform
expression. RT-PCR using primers that can simultaneously
amplify both VEGFxxx and VEGFxxxb species, we believe,
provides the most reliable approach. Similarity between
VEGFxxx/VEGFxxxb splice junction sequences in both mouse
and human VEGF-A genes infers that the issues we highlight
associated with interpreting VEGFxxxb isoform-specific RT-
PCR mouse data can be extrapolated to include human data
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also, leaving us with the conundrum of why our experiments
using human cDNAs failed to reveal authentic VEGFxxxb
products. Consistent with our mouse data, the most obvious
explanation is that VEGFxxxb products are not commonly
expressed in the human cells and tissues we examined.
Alternatively, they may be expressed at physiological levels
below the limits of detection. Importantly, reports highlighting
the anti-tumour effects of VEGF165b are based on in vivo
studies using recombinant VEGF165b or overexpression of
VEGF165b. Moreover, downstream signalling effects associated
with endogenous VEGFxxxb isoforms remain, so far, un-
reported. Interestingly, Catena et al., recently report that
VEGF121b and VEGF165b are weakly angiogenic rather than
anti-angiogenic and upregulated rather than downregulated in
breast cancer [55]. Consistent with our study, this data
contradicts previous literature, and we believe adds strength to
our hypothesis of xxxb primer ‘mispriming’ from existing
VEGFxxx transcripts, since analysis of the primer design used
in this study indicates VEGFxxxb isoform specific primers with
significant homology to exons 5 (20 bases) or 7 (23 bases).
These isoforms could therefore be VEGFxxx species with
artefactual exon8b ‘tails’ which could therefore be weakly
angiogenic compared to conventional VEGFxxx proteins, but
would still be expected to be upregulated in cancer. Considering
the potential importance associated with VEGFxxxb isofoms,
our data, together with this data highlight the need for further
clarification of many aspects of VEGFxxxb biology; the
physiological existence of these isoforms, their expression levels
and consequently their biological significance in keeping
angiogenesis in check.
Supporting Information
Data S1 Provides supporting text showing methods,
results and figure relating to characterisation of murine
VEGF isoform expression by Western blotting and mass
spectrometry.
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